Welcome Home Contact Us News/Events
Home

© Teesside Prostate Cancer Support Group. All rights reserved.  Last updated 20 April 2018

Newsletter


Upcoming Events

We have 3 volunteers so far for the planned walk for PCUK from Hartlepool FC to Darlington FC 27 miles walk 9th June, if you want to get involved there will be a need for bucket shakers,marshalls, first aiders etc etc required on the day.

Please let Robin Millman know asap if want to get involved with this event.

Cycle to the Moon Save a Dad You can organise your own cycling event by yourself, with your friends and family, outdoors or indoors and get people to sponsor you. Go online to register and get involved in this latest TACKLE project. See link below:- http://cycletothemoon.tackleprostate.org/

What The Papers Are Saying

Daily Mail 29th Mar 2018 Prostate Drug That Is More Effective Ater A “Full English”

Eating a full English breakfast could make a leading prostate cancer treatment more effective, a study has found. Fatty foods may allow the drug Abiraterone – which can extend the lives of patients with advanced prostate cancer – to be absorbed ten times more easily, researchers say.

NHS guidelines say it must be taken on an empty stomach, but the University of Chicago researchers suggest taking it with a high-fat meal of around 825 calories could make it more effective. The study of 72 patients over 12 weeks published in the Journal of Clinical Oncology, found that even a low-fat breakfast of cereal and skimmed milk improved the drug’s absorption by 4 to 5 times. Lower doses could save the NHS thousands of pounds. Newsletter’s Editor Comment: “You can take it with a pinch of salt”

Daily Mail 8th Feb 18

Precision Drug For Prostate May Help 3,000 Cancer Patients

Prostate cancer care is set to be transformed by the use of the first personalised medicine to tackle the disease. British scientists are leading a global trial of a daily pill that uses a man’s genetic make-up to undermine a tumour’s defences. Early results suggest a third of victims of advanced prostate cancer could benefit from the new class of drugs called PARP-inhibitors – potentially helping 3,000 men a year.

Experts at the Institute of Cancer Research in London have now embarked on a phase 3 trial of one of these drugs, called olaparib, involving 350 patients with prostate cancer. If the trials are successful it will pave the way for the first personalised, or precision medicines for prostate cancer. Professor Johann de Bono was among the team that found men and woman with a mutated BRCA gene could be treated by the new drugs. The treatment works by zeroing in on cancer cells’ weak points to kill them without harming healthy cells.

Yet despite the discovery, pharmaceutical companies were interested only in tackling ovarian and breast cancer. Through Professor Johann de Bono’s persistence – and fund raising from Cancer Research UK and the Movember campaign – the same trials were launched for prostate cancer.

Newsletter’s Editor Comment: “Watch this space”

Daily Mail 8th Feb 18

A Balloon That Can
Cut Cancer Side Effects

 Using a balloon during radiotherapy for prostate cancer is being tested as a way to spare men damaging side-effects. The balloon is positioned next to the prostate to prevent radiation reaching healthy tissues around the gland, such as the rectum. The idea is that doctors can then target higher doses of radiation directly at the prostate to kill the tumour more effectively. n a new trial at the Urology Nevada Clinic in the United States, 222 patients undergoing radiotherapy will have the balloon inserted via a minimally invasive procedure under local anaesthetic. It will be inflated with saline to create a safe gap between the tumour and healthy tissue.

Newsletter’s Editor Comment: “Up, up and away”

Daily Mail 10th Apr 18

Plug That Stops Men
Rushing For The Loo

 A plastic plug could help treat incontinence in men who’ve undergone surgery to remove the prostate gland. Designed and developed by a prostate cancer patient left incontinent after the operation, the plug is now being tested in a clinical trial in Canada. The problem occurs as a result of nerves and muscles that control the bladder become damaged during the operation, with approximately one in five prostate cancer patients thought to experience leaks in the long term as a result. The most common problem is stress incontinence, meaning men leak when they cough, sneeze or exercise. This occurs because of the damage to the muscular valve – the bladder sphincter – that keeps urine in the bladder. The device, called the Comfort Plug, looks like a tiny, tapered spinning top and is made of soft plastic. It is said to be painless to use and is inserted into the urethra by the patient themselves, using a thin stick that clips on to the top of the plug. The plug is pushed until it reaches an area called the bulbar urethra, which is around 2 – 3 cm in length, between the sphincter and the base of the penis. The plug is kept in all day and the user can simply remove it when they need to go to the loo. Patients will be given guidance on how to insert, remove and clean the plug.

Further Follow-up Of
Chemohormonal Treatment

The American trial that a couple of years ago reported at the same time as STAMPEDE on adding docetaxel to hormone therapy (HT) – the combination together being known as chemohormonal therapy (CT) - has updated some results. After four and a half years of follow up the overall survival benefit for all men on CT was 58 months versus 47 months for HT alone. However the benefit for men with high volume disease was significantly better at 51 months (CT) versus 34 months (HT). High volume disease was defined as metastatic disease of either/or both soft tissue or 4 or more bone mets.There was no significant overall survival benefit for men with low volume disease.

 Information was researched and provided by Robin Millman

Late Diagnosis - Extra Funding

 Two items on PC have just made news in the national media. Firstly a men’s charity called Orchid published a report on the worrying level of late diagnosis in PC. The figures show that in 37% of cases men are diagnosed with stage III or IV disease. These advanced stages of disease mean curative treatment is not possible or very difficult. Alarmingly, but something men with the disease in support groups would recognise, 42% of diagnosed men had seen their GP at least twice with worrying symptoms and 6% had seen a GP at least 5 times about symptoms. Clearly there is still a lot to do around PC awareness with men (and their families) and GP’s. On the same day the Government announced a £75m 5-year funding package for research into PC. It is hoped around 60 new studies will look into things like high risk groups (black men and family history); precision radiotherapy; HIFU; cryotherapy and exercise and diet.

Information was researched and provided by Robin Millman

Daily Mail 24th Mar 18

Prostate Treatment
That Takes Just 5 Days

Men with prostate cancer could benefit from radical radiotherapy treatment in just 5 days instead of the usual 37 days. At the moment, patients must go to hospital from Monday to Friday every week for nearly two months. But doctors in London are conducting a major trial to deliver a more powerful therapy in 5 daily sessions. As well as being more convenient for men, it will save the NHS millions of pounds, and scientists believe it could also reduce the side effects. A trial of 1,800 patients has started at the Royal Marsden Hospital and the Institute of Cancer Research in London. They receive either surgery or a 5 day, 37 day or 20 day radiotherapy course. Scientists will monitor the men for 5 years to see whether the 5 day course is as effective at defeating prostate cancer as the others. The trial involves boosting the radiation power to more than twice the original dose over fewer treatments.

 All Newspaper Information was collected and provided by Tina Rowley

Read Our News Letter In Full